Exploring the medication pattern and mechanism of action of traditional Chinese medicine in treating polycystic ovary syndrome with kidney deficiency and blood stasis based on data mining and network pharmacology

Background:Using network pharmacology to explore the potential molecular mechanism of traditional Chinese medicine in treating polycystic ovary syndrome(PCOS)with kidney deficiency and blood stasis syndrome.Method:Collect the related literature materials of PCOS with kidney deficiency and blood stasis syndrome treated by traditional Chinese medicine in four databases in recent ten years,extract the information of prescriptions and complete the frequency analysis.Traditional Chinese Medicine Systems Pharmacology Database was used to screen out the effective components.Use Online Mendelian Inheritance in Man and other databases to screen PCOS disease targets.The intersection targets obtained by clustering prescription and PCOS disease targets were submitted to STRING database for protein-protein interaction network analysis,and Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes pathways were analysed by Metascape.Result:There are 155 kinds of traditional Chinese medicines used in the literature.The most commonly utilized ones are Cuscutae Semen,Angelicae Sinensis Radix,and Rehmanniae Radix Praeparata.The results of the cluster analysis indicated that the plants most commonly found throughout the prescription were Leonuri Herba,Lycopi Herba,Dipsaci Radix,etc.GO results show that biological processes include cell reaction to organic nitrogen compounds and cell reaction to nitrogen compounds.The functional display of GO molecule includes cytokine receptor binding,signal receptor regulator activity and so on.Kyoto Encyclopedia of Genes and Genomes results show that the possible mechanisms of action are cancer pathway,an endocrine resistance signal pathway.Conclusion:Through data mining,the cluster prescription for PCOS with kidney deficiency and blood stasis syndrome is Leonuri Herba,Lycopi Herba,Dipsaci Radix,etc.The network pharmacology research of cluster prescription shows that the main drug components for treating PCOS with kidney deficiency and blood stasis syndrome are quercetin,kaempferol,luteolin,tanshinone IIA,etc.,which act on PTGS2,NCOA2,and other targets,and treat PCOS with kidney deficiency and blood stasis syndrome through cancer and endocrine resistance.

Clinical Nursing Intervention of Moxibustion on Abdominal Distension Symptoms in Heart Failure (Heart and Kidney Yang Deficiency and Blood Stasis Blocking Collaterals Syndrome)

Objective:To investigate the clinical nursing intervention effect of moxibustion on abdominal distension symptoms in heart failure(heart and kidney yang deficiency and blood stasis blocking collaterals syndrome).Methods:62 patients with heart failure(heart and kidney yang deficiency and blood stasis blocking collaterals syndrome)admitted to our hospital from February 2023 to February 2024 were selected and divided into the observation group(n=31)and the control group(n=31)by using the random numerical table method.The control group adopted conventional nursing interventions,and the observation group received the nursing program of the control group with the addition of moxibustion nursing interventions.The nursing effectiveness,quality of life scores,and nursing satisfaction were compared between the two groups.Results:The nursing effectiveness of the observation group was significantly higher than the control group(P<0.05);the quality of life score of the observation group was significantly higher than the control group(P<0.05);the nursing satisfaction of the observation group was significantly higher than that of the control group(P<0.05).Conclusion:The use of moxibustion nursing intervention in patients with heart failure(heart and kidney yang deficiency and blood stasis blocking collaterals syndrome)can effectively relieve the symptoms of abdominal distension,improve patients'quality of life,and increase nursing satisfaction,which has promotion and application values.

Clinical observation on efficacy of compound of warming yang, descending turbidity and dredging collaterals in the treatment of diabetic kidney disease with Yin-Yang deficiency and blood stasis syndrome

Objective:To observe the clinical efficacy of compound of owarming yang,descending turbidity and dredging collaterals in the treatment of diabetic kidney disease with yin-yang deficiency and blood stasis syndrome.Methods:Seventy-six patients of diabetic kidney disease with yin-yang deficiency and blood stasis syndrome were randomly divided into observation group and control group,thirty-eight cases in each group.The control group was given conventional western medicine treatment,while the observation group took compound of owarming yang,descending turbidity and dredging collaterals orally on the basis of conventional western medicine treatment.The course of treatment covered for one month.Before and after treatment,we observed the scores of traditional Chinese medicine symptoms,indicators of renal function[serum creatinine(Scr),blood urea nitrogen(BUN),microalbuminuria(MALB)],indicators of glucose metabolism[fasting plasma glucose(FPG),2-hour postprandial blood glucose(2hPG),glycosylated hemoglobin(HbAlc)],indicators of hemorheology[plasma viscosity(PV),platelet aggregation rate(PAR),fibrinogen(FIB)],Cystatin-C(Cys-C),C-reactive protein(CRP)in the two groups.Results:After treatment,the clinical effect of the observation group was significantly better than the control group(P<0.05).The scores of traditional Chinese medicine symptoms,indicators of renal function(Scr、BUN、UAER),indicators of glucose metabolism(FPG、2hPG、HbAlc),indicators of hemorheology(PV、PAR、FIB),Cys-C and CRP in the two groups were decreased significantly compared with those before treatment(P<0.05),and the decrease in the observation group was superior to that in the control group(P<0.05).Conclusion:Compound of warming yang,descending turbidity and dredging collaterals has remarkable efficacy in treating of diabetic kidney disease patients with yin-yang deficiency and blood stasis syndrome by alleviating clinical symptoms,glucose metabolism,renal function and microcirculatory disturbance,and the mechanism related to alleviation of microinflammation.

Application of Stone Needle Therapy Based on Blood Stasis Theory in the Treatment of 36 Cases of Knee Osteoarthritis in Early and Middle Stage

Objective:To evaluate the clinical efficacy of stone needle therapy based on blood stasis theory for different traditional Chinese medicine(TCM)syndrome types of patients with knee osteoarthritis in early and middle stage.Methods:Totally 36 patients with knee osteoarthritis were enrolled in the orthopaedic ward between March 2016 and December 2017,and diagnosed as qi stagnation and blood stasis syndrome,cold dampness and stasis syndrome,or phlegm and stasis syndrome according to TCM syndrome differentiation.After treatment,stone needle was used for ironing on the different meridian acupoints according to different syndrome.The efficacy of patients with the above three syndromes was respectively evaluated,and the visual analogue scale(VAS)score and western ontario and mcMaster universities arthritis Index(WOMAC)score of the three groups were calculated before treatment,2 weeks,and 4 weeks after treatment.Results:The effective rates of the three groups were 86.67%,81.82%,and 80.00%,respectively.After 2 weeks and 4 weeks of treatment,the VAS and WOMAC scores of the three groups decreased significantly compared to treatment before(P<0.05).Conclusion:Stone needle therapy for ironing on the acupoints around the knee joint has a good therapeutic effect on knee osteoarthritis of different syndrome types,which is worthy of further application.

活血除痹汤联合膝痹止痛针法治疗膝骨性关节炎的临床疗效

目的观察活血除痹汤联合膝痹止痛针法治疗膝骨性关节炎(KOA)的临床疗效。方法将确诊为KOA患者72例随机分为治疗组和对照组,各36例。对照组采用膝痹止痛针法治疗,治疗组膝采用痹止痛针法联合活血除痹汤治疗,治疗4周后观察2组治疗前后中医症候评分、视觉模拟评分(VAS)、西安大略和麦克马斯特大学骨关节炎指数(WOMAC Osteoarthritis Index)、日本骨科协会评估治疗分数(JOA Scores)变化,并进行组间对比。结果治疗后,2组中医症候评分、VAS评分、WOMAC评分均较治疗前降低,且治疗4周后的治疗组较对照组更低,差异有统计学意义(P<0.05);治疗后,2组JOA评分较治疗前明显增高,且治疗4周后的治疗组较对照组更高,差异有统计学意义(P<0.05);治疗组的总有效率为91.67%,对照组为72.22%,治疗组疗效明显优于对照组,差异有统计学意义(P<0.05)。结论单纯膝痹止痛针法可缓解疼痛,联合活血除痹汤可增强其止痛疗效,并能有效改善关节肿胀及活动度,值得推广。

肾虚血瘀型SD大鼠膝骨关节炎模型的建立与验证

背景:肾虚血瘀证候作为膝骨关节炎常见中医证候,又是膝骨关节炎的基本病机,二者之间有着重要联系。但肾虚血瘀证候如何促进膝关节软骨损伤及其潜在机制并不明确,还需进一步研究。目的:探讨肾虚血瘀证候对SD大鼠膝骨关节炎进程的影响。方法:将16只SD大鼠随机分为模型观察组和对照组,每组8只。模型观察组采用卵巢摘除方法建立肾虚模型,2个月后采用改良HULTH手术进行膝骨关节炎造模,HULTH手术后1周皮下注射盐酸肾上腺素进行血瘀造模;对照组给予卵巢摘除假手术,改良HULTH手术,皮下注射生理盐水。HULTH手术后第5周,检测血液流变学、凝血四项、三碘甲状腺原氨酸、四碘甲状腺原氨酸及雌二醇水平;同时,拍摄膝关节X射线片,进行膝关节苏木精-伊红染色、番红-固绿染色和免疫组化染色。结果与结论:①与对照组相比,模型观察组全血黏度低切、中切、高切和血浆黏度显著升高,凝血四项中纤维蛋白原水平显著升高,凝血酶原时间和活化部分凝血活酶时间显著下降;三碘甲状腺原氨酸、四碘甲状腺原氨酸及雌二醇水平均显著下降;②影像学结果显示模型观察组大鼠膝关节间隙狭窄程度更严重且表面欠光滑,出现高密度影;③苏木精-伊红染色和番红-固绿染色表明,模型观察组大鼠软骨损伤更严重,并且OARSI评分和Mankin评分明显高于对照组;④免疫组化染色结果显示,相较于对照组,模型观察组大鼠软骨外基质Ⅱ型胶原、聚集蛋白聚糖蛋白表达显著下降,炎症因子基质金属蛋白酶13、解聚蛋白样金属蛋白酶5蛋白表达显著升高。结果表明,该研究成功建立了SD大鼠肾虚血瘀型膝骨关节炎模型;肾虚血瘀证候通过促进炎症因子表达进一步加重软骨外基质裂解和软骨退变,促进大鼠膝骨关节炎进程。

膝骨关节炎不同证候患者关节液BMP-2和CTGF浓度特点及其与证候程度间的相关性研究

目的研究膝骨关节炎肝肾亏虚证和痰瘀互结证患者关节液骨形态发生蛋白-2(BMP-2)和结缔组织生长因子(CTGF)的浓度特点及其与证候程度间的相关性。方法留取并测定89例膝骨关节炎不同证候患者关节液BMP-2和CTGF的浓度,应用中医证候评分量表量化证候程度,分析关节液BMP-2和CTGF的浓度特点及其与证候程度间的相关性。结果膝骨关节炎痰瘀互结证和肝肾亏虚证患者年龄、身高、体质量、生命体征、病程比较上差异未见统计学意义(P>0.05);膝骨关节炎肝肾亏虚证患者关节液BMP-2的浓度水平显著高于痰瘀互结证患者(z=-2.212,P<0.05);膝骨关节炎肝肾亏虚证患者关节液CTGF的浓度水平显著低于痰瘀互结证患者(z=-2.072,P<0.05);膝骨关节炎肝肾亏虚证患者关节液CTGF浓度水平与中医证候评分呈负相关(r^(2)=0.240,P<0.05)。结论膝骨关节炎痰瘀互结证和肝肾亏虚证患者关节液BMP-2和CTGF浓度特点不同,肝肾亏虚证患者关节液CTGF浓度可以在一定程度上反映其证候的严重程度,上述发现与中医病因病机的分析相一致,其作用机制可能与转化生长因子β(TGF-β)/Smad信号通路的激活程度不同有关。

以“血瘀”理论指导治疗:解读膝骨关节炎“铁超载”的相关机制

背景:膝骨关节炎多发于中老年人,是一类严重影响患者的生活质量甚至有致残风险的疾病。因此,膝骨关节炎的发病机制以及治疗手段已成为研究的焦点。在祖国医学中,膝骨关节炎常以“痹”论治,并与中医“血瘀”理论中血行瘀滞、血脉阻络而致之“痹”紧密相关。铁超载是一类因铁代谢紊乱导致的病理状态,其与中医“血瘀”理论的发病特点、临床表现等高度重合,是促进膝骨关节炎发展的危险因素。目的:基于“血瘀”理论,就铁超载对软骨代谢以及软骨下骨重建的影响展开综述,为中医药治疗膝骨关节炎奠定了全新理论基础,也为探究活血中药干预骨组织后期治疗作用的相关机制提供理论依据。方法:通过检索中国知网、万方数据、PubMed及Web of Science数据库获得文献,中文检索词为“铁死亡,铁,铁超载,骨关节炎,血瘀”以及英文检索词为“ferroptosis,iron,iron overload,osteoarthritis,TCM”,最终纳入文献76篇进行综述分析。结果与结论:①文章针对“血瘀”理论治疗膝骨关节炎的潜力进行发掘,发现“血瘀”是膝骨关节炎进展中至关重要的部分,表明“血瘀”理论是中医治疗膝骨关节炎的关键所在。②“血瘀”与铁超载在致病因素、临床表现、发病特点上有高度的相似性,提示了“血瘀”理论治疗铁超载的可能性,说明铁超载可能是“血瘀”理论治疗膝骨关节炎的重要机制基础,活血类药物的提取物有着缓解铁超载并治疗膝骨关节炎的作用,但具体机制尚不明确。③“血瘀”理论与铁超载的关系及相关机制是未来膝骨关节炎的重要研究方向,可为中医临床开发新药、创新用法等中医现代化手段提供了理论基础,对临床有一定的指导意义。

补肾活骨汤治疗肾虚血瘀型膝骨关节炎临床研究及药效学验证

目的通过肾虚血瘀型膝骨关节炎(knee osteoarthritis,KOA)患者的临床研究和KOA大鼠模型的药效学验证,评价中药复方补肾活骨汤治疗KOA的疗效,并初步探究该方的作用机制。方法临床研究采用随机对照研究方法,纳入肾虚血瘀型KOA患者共92例,其中对照组42例,观察组50例。两组均予基础治疗及玻璃酸钠关节腔注射治疗,观察组在此基础上加用补肾活骨汤中药口服治疗,比较治疗前、治疗1周后、治疗4周后疼痛视觉模拟评分(VAS)、膝关节功能Lequesne评分差值、客观量化指标(包括关节压痛、关节肿胀、关节僵硬)及中医证候积分。药效学验证选择前交叉韧带切除术(ACLT)建立KOA大鼠模型,将48只SD大鼠随机分成假手术组,模型组,阳性药组,补肾活骨汤高、中、低剂量组,中药组予不同剂量的补肾活骨汤连续灌胃给药2个月,采用HE染色、番红O/固绿染色和OARSI组织学评分确证补肾活骨汤治疗KOA大鼠的药效。结果(1)VAS评分。两组患者VAS较本组治疗前均有所改善(P<0.01);治疗1周后,两组患者VAS比较差异无统计学意义(P>0.05),治疗4周后,观察组更优(P<0.01)。(2)Lequesne评分。治疗1周和治疗4周后,观察组Lequesne总分与治疗前总分的差值较对照组下降更多(P<0.01),且治疗后疼痛或不适程度评分与治疗前该项评分的差值较对照组下降更显著(P<0.01),治疗后生活能力评分与治疗前该项评分的差值亦较对照组下降更多(P<0.01),两组患者行走能力与治疗前相比均改善,但差异无统计学意义(P>0.05)。(3)客观量化指标。两组患者关节压痛、关节肿胀、关节僵硬指标评分均较治疗前改善,治疗1周后,观察组在改善关节肿胀方面较对照组更优(P<0.05);治疗4周后,观察组关节压痛、关节肿胀、关节僵硬的改善程度均优于对照组(P<0.05)。(4)中医证候积分。治疗1周后,观察组中医证候积分较对照组下降更多(P<0.05),且较对照组能更好地改善患者的关节畏寒、倦怠乏力症状(P<0.05),对照组倦怠乏力症状评分与治疗前相比差异无统计学意义(P>0.05)。治疗4周后,观察组能显著改善关节畏寒、腰膝酸软、倦怠乏力症状,且较对照组更优(P<0.05)。(5)HE染色。给药2个月后,补肾活骨汤高剂量组与模型组相比软骨表面更光滑,软骨细胞数目明显增多,且排列更为整齐。(6)番红O/固绿染色。与模型组相比,补肾活骨汤高剂量组蛋白聚糖含量明显增加,随着中药剂量不断增加,大鼠OARSI组织学评分连续下降。结论补肾活骨汤能有效地缓解KOA患者的膝关节疼痛,改善膝关节功能,提高KOA患者的心理、生活质量,值得临床借鉴推广。

基于TLR4/NF-κB信号通路探讨川膝散对肾虚血瘀型膝骨性关节炎的作用机制

目的:探讨川膝散通过TLR4/NF-κB信号通路对肾虚血瘀型膝骨性关节炎的作用机制。方法:纳入2021年1月—2022年12月至杭州市富阳中医骨伤医院就诊的膝骨性关节炎患者90例,随机分为对照组和观察组,每组各45例。对照组接受股四头肌锻炼、外用消炎止痛膏及口服硫酸氨基葡萄糖治疗,观察组接受对照组治疗的同时增加川膝散治疗。治疗前和治疗1个月后对两组患者进行膝关节疼痛VAS评分、JOA评分、WOMAC骨关节炎指数评分并检测血清Toll样受体4(TLR4)、核因子κB p65(NF-κB p65)、白介素1b(IL-1b)、肿瘤坏死因子α(TNF-α)变化。结果:两组患者膝关节疼痛VAS评分、JOA评分及WOMAC评分治疗前比较无明显统计学差异(P>0.05);治疗1个月后,两组患者VAS评分、JOA评分及WOMAC评分均较治疗前有改善,差异具有统计学意义(P<0.05);与对照组比较,观察组VAS评分及WOMAC评分更低,而JOA评分更高,差异具有统计学意义(P<0.05)。两组患者治疗前血清TLR4、NF-κB p65、IL-1b、TNF-α水平比较无明显统计学差异(P>0.05);治疗1个月后,两组患者血清TLR4、NF-κB p65、IL-1b、TNF-α水平较治疗前降低(P<0.05),观察组患者血清TLR4、NF-κB p65、IL-1b、TNF-α水平明显低于对照组,差异具有统计学意义(P<0.05)。结论:川膝散可以通过肾虚血瘀型膝骨性关节炎患者TLR4/NF-κB信号通路的激活,减少促炎因子的释放,从而减轻膝关节疼痛症状,改善患者膝关节功能的作用。

从“虚、瘀、毒”论治膝关节骨性关节炎的临床研究

目的:观察从"虚、瘀、毒"立论的加味独活寄生合剂治疗膝骨性关节炎的临床疗效。方法:将64例膝关节患者随机分为治疗组和对照组各32例,治疗组予加味独活寄生合剂配合玻璃酸钠注射液治疗,对照组予玻璃酸钠注射液治疗,5周后观察两组疗效。结果:两组治疗前后VAS评分均降低,差异有统计学意义(P<0.05);治疗后两组VAS评分比较,治疗组低于对照组(P<0.05);治疗组治疗后膝关节功能WOMAC评分优于对照组,差异有统计学意义(P<0.05)。结论:加味独活寄生合剂可减轻膝骨性关节炎患者疼痛,改善膝关节功能。

瘀血阻滞型膝骨性关节炎与其关节镜下病理改变及细胞因子相关性

目的:探讨瘀血阻滞型膝骨性关节炎与细胞因子及关节镜下病理改变之间的相关性,为中医临床诊治提供客观量化指标。方法:2009年2月至2010年3月膝骨性关节炎住院患者90例,男17例,女73例;年龄40～70岁,平均57.2岁;病程1个月～10年,平均3.4年;左膝31例,右膝59例。对纳入病例行中医辨证,选择瘀血阻滞型患者,术前均有膝关节固定刺痛、晨僵,大部分有交锁现象,均无关节肿胀。术前采集关节液,ELISA法测定细胞因子白细胞介素1β(IL1β)、转化生长因子β1(TGFβ1)的含量,同时在关节镜下观察关节内病理改变。综合以上资料探讨瘀血阻滞型膝骨性关节炎病变程度,同时对不同类型关节镜下病理改变与细胞因子水平进行相关性分析。结果:关节液IL1β和TGFβ1水平分别为(28.18±5.57)pg/ml和(51.69±6.56)pg/ml。Ⅲ～Ⅳ度软骨退变组IL1β水平为(30.65±3.48)pg/ml,高于Ⅰ～Ⅱ度软骨退变组的(20.55±3.50)pg/ml;Ⅰ～Ⅱ度软骨退变组TGFβ1水平为(58.18±3.98)pg/ml,高于Ⅲ～Ⅳ度软骨退变组的(49.59±5.83)pg/ml,差异有统计学意义(P<0.01);IL1β与软骨退变呈正相关,r=0.744,TGFβ1与软骨退变呈负相关,r=-0.563。Ⅱ～Ⅲ度滑膜增生组IL1β水平为(33.48±2.95)pg/ml,高于Ⅰ度滑膜增生组的(25.40±4.50)pg/ml,差异有统计学意义(P<0.01);IL1β与滑膜增生呈正相关,r=0.801。Ⅰ级骨赘增生组IL1β水平为(34.18±2.69)pg/ml,高于0级骨赘增生组的(25.74±4.48)pg/ml;0级骨赘增生组TGFβ1水平为(53.11±6.78)pg/ml,高于Ⅰ级骨赘增生组的(48.21±4.47)pg/ml,差异有统计学意义(P<0.01);IL1β与骨赘增生呈正相关,r=0.762;TGFβ1与骨赘增生呈负相关,r=-0.340。结论:瘀血阻滞型膝骨性关节炎患者存在关节软骨退变、滑膜增生等病理改变,IL1β水平对软骨退变、滑膜增生和骨赘增生程度的估计有重要参考价值。

止痛四物汤对肾虚血瘀型膝骨性关节炎患者关节液中MMP-3、NO、IL-1的影响

目的:观察止痛四物汤对肾虚血瘀型膝骨性关节炎患者关节液中MMP-3、N0、IL-1的影响。方法:将60例符合标准的膝骨关节炎患者按随机数字表法分为两组,每组30例。Ⅰ组患者口服美洛昔康分散片;Ⅱ组患者口服中药止痛四物汤。分别于治疗前、治疗后3周及6周抽取膝关节液检测MMP-3、NO、IL-1的含量。结果:治疗前和治疗3周后两组间的MMP-3、NO、IL-1含量比较差异均无统计学意义(P>0.05);治疗6周后Ⅱ组的MMP-3、NO、IL-1含量均较Ⅰ组下降明显,差异均有统计学意义(P<0.05)。结论:止痛四物汤能降低肾虚血瘀型膝骨性关节炎患者关节液中MMP-3、NO、IL-1的含量,抑制炎性反应,值得临床推广。

桃红四物液治疗“气滞血瘀型”膝骨关节炎疗效研究

目的观察桃红四物液治疗"气滞血瘀型"膝骨关节炎的临床疗效。方法116例患者随机分为治疗组和对照组,两组各58例,对照组膝关节腔注射玻璃酸纳注射液,按说明每周1次,连续5次,治疗结束后1周(总周期5周)后进行疗效评定,治疗组在对照组的基础上,每日口服桃红四物液50 m L/次,2次/d,连用4周,治疗结束1周(总周期5周)后进行疗效评定。结果VAS评分结果:治疗后VAS评分两组均较治疗前有所降低,差异有统计学意义(P<0.05);治疗后两组间比较,治疗组疼痛VAS评分较对照组低,差异有统计学意义(P<0.05);膝关节功能WOMAC评分结果:治疗后WOMAC评分两组均较治疗前低,差异有统计学意义(P<0.05);治疗后两组间比较,治疗组WOMAC评分明显较对照组为低,差异有统计学意义(P<0.05);有效率比较结果:治疗组高于对照组,差异有统计学意义(P<0.05)。结论桃红四物液治疗KOA在减轻关节疼痛、改善关节功能等方面有较好的临床效果。

刘德玉从虚、瘀论治膝骨性关节炎

刘德玉教授认为,膝关节骨性关节炎(KOA)的中医病因病机特点是肝肾亏虚与瘀血痹阻并存,虚致瘀,瘀又加重虚,两者相互作用,形成恶性循环。本病属于本虚标实,肝肾亏虚为其发病的根本,瘀血阻痹为其发病的关键。肝肾亏虚,肾精虚弱,无力化肝血,致使血不荣筋骨;气血不足,运行不畅,致使瘀血阻滞;不荣则痛、不通则痛致使关节疼痛、筋脉拘挛、屈伸不利而发病。治疗当以补益肝肾、活血化瘀、通络止痛为原则,从而达到标本兼治的目的,也体现了急则治其标、缓则治其本的学术思想和其三位一体的诊疗思想。

膝痛康治疗肾虚血瘀型膝骨性关节炎疗效评价

目的观察膝痛康治疗肾虚血瘀型膝骨性关节炎(knee osteoarthritis,KOA)的临床有效性与安全性,为膝痛康进一步临床推广应用提供依据。方法将3家医院176例合格受试者随机分为试验组88例和对照组88例。试验组采用基础治疗+膝痛康内服,对照组采用基础治疗+安慰剂内服,疗程4周。治疗期间,两组受试者出现不耐受疼痛时均可在医师指导下服用洛索洛芬钠片。试验开始前和结束时,采用NRS评分、WOMAC评分、ADL评分、中医病证诊断疗效量表评分和相关安全性指标检测评价该药的有效性和安全性。结果两组(疗前-疗后)NRS评分、WOMAC评分、ADL评分和中医病证诊断疗效量表评分比较,均有明显统计学意义(P<0.01);两组疗后各评分比较,试验组明显优于对照组(P<0.01);两组各评分有效率组间比较,试验组有效率高于对照组(P<0.01)。结论膝痛康治疗肾虚血瘀型KOA疗效确切,值得临床推广应用。

仇湘中教授从肝论治膝骨关节炎经验

仇湘中教授认为膝骨关节炎临床表现为虚实夹杂之症,主要病机为肝虚、血瘀,治疗上强调补肝通络,针对此病总结出"补肝健膝方",为膝骨关节炎的临床治疗提供有效的方法。

基于“腠理开阖”理论的黑膏药对寒凝血瘀证膝骨关节炎模型家兔血管反应性研究

目的:通过寒凝血瘀证膝骨关节炎模型家兔的血管反应性研究,评价黑膏药促“腠理开阖”的作用机制。方法:选用寒凉刺激与药物诱导结合技术制备寒凝血瘀证膝骨关节炎家兔模型,采用彩色多普勒超声技术并辅以血液流变学指标,密切观察家兔膝周动脉网(股动脉下段、膝上外侧动脉和膝下外侧动脉)血管效应,考察0~15 d三个厂家狗皮膏(厂家一组、厂家二组和厂家三组)与黑膏药基质(基质组)对膝周动脉网的管径、血流速度及血液流变学指标的影响。结果:15 d治疗周期后,厂家一组、厂家二组、厂家三组和基质组家兔股动脉下段、膝上外侧动脉和膝下外侧动脉血管管径均有增加,流速均有提高,全血黏度、红细胞聚集指数均呈现降低趋势,红细胞变形指数呈现升高趋势。结论:黑膏药基质与狗皮膏均表现出显著的诱发膝周动脉网血管效应的作用,提示在促进“腠理开阖”方面,黑膏药基质同样起到了关键作用。

肾虚血瘀型膝关节骨性关节炎关节镜下软骨损伤特征及相关因素研究

目的探索肾虚血瘀型膝关节骨性关节炎软骨损伤特征及相关影响因素。方法选择符合中西医诊断标准的病人,术前采集其基本信息、胫股角、软骨厚度,并在术后记录软骨损伤镜下分级。结果共纳入31例病例,年龄主要分布在60~69岁。31例患者共有186处软骨,其中13处为正常软骨,173处软骨有损伤,股骨内髁、髌骨、股骨髁间窝及滑车这3个区域软骨损伤无明显差异(P>0.05),且较其他部位严重(P<0.05),胫骨外侧平台损伤最轻。WOMAC评分和Lysholm评分与软骨损伤程度无明显的相关性(P>0.05)。股骨内髁软骨损伤分级与年龄的相关性不显著(P>0.05)。股骨内髁软骨损伤分级与体质量指数、胫股角呈正相关(P<0.05)。各部位的软骨损伤分级与相应部位的软骨厚度呈负相关(P<0.05)。结论股骨内髁、髌骨、股骨髁间窝及滑车的软骨损伤程度较其他部位严重,胫骨外侧平台损伤最轻;临床症状体征和关节功能与软骨损伤的程度没有绝对的相关性;年龄对于软骨损伤的影响没有显著意义;体质量指数和胫股角越大,股骨内髁软骨损伤分级越高;各部位软骨损伤的镜下分级越高,MRI下测量的软骨厚度越小。

骨炎定方治疗肝肾不足气虚血瘀型膝骨关节炎54例疗效观察

【目的】观察和评价骨炎定方治疗肝肾不足气虚血瘀型膝骨关节炎(OA)患者的临床疗效。【方法】将106例膝OA患者随机分为治疗组54例和对照组52例。治疗组服用骨炎定方(由黄芪、红花、骨碎补、补骨脂、木瓜、牛膝等药物组成),对照组服用塞来昔布。2组均以4周为1个疗程,治疗3个疗程后进行疗效比较,并评价其安全性。【结果】总有效率治疗组为94.44%,对照组为82.70%,2组比较差异有显著性意义(P<0.05),且2组在观察期间各项实验室检测指标均基本正常,未出现不良反应。【结论】骨炎定方能有效改善肝肾不足、气虚血瘀型膝OA患者的临床症状,疗效优于塞来昔布,并可有效地缓解膝关节疼痛,改善膝关节功能,药物安全性好,无明显毒副作用。